Improved survival with vemurafenib in melanoma with BRAF V600E mutation, NEJM, vol.364, issue.26, pp.2507-2516, 2011. ,
Inhibition of mutated, activated BRAF in metastatic melanoma, NEJM, vol.363, issue.9, pp.809-819, 2010. ,
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, Lancet Oncol, vol.15, issue.3, pp.323-355, 2014. ,
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, vol.380, issue.9839, pp.358-365, 2012. ,
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma, NEJM, vol.377, pp.1813-1836, 2017. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, issue.6892, pp.949-54, 2002. ,
A selective RAF kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RAFV600E mutation, Abstract B88, vol.8, 2009. ,
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, vol.467, issue.7315, pp.596-599, 2010. ,
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, NEJM, vol.371, issue.20, pp.1877-88, 2014. ,
Combined vemurafenib and cobimetinib in BRAFmutated melanoma, NEJM, vol.371, issue.20, pp.1867-76, 2014. ,
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization, Mol Cell, vol.20, issue.6, pp.963-972, 2005. ,
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF, BMC Cancer, vol.15, p.779, 2015. ,
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy, Int J Cancer, vol.138, issue.4, pp.881-90, 2016. ,
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition, Clin Cancer Res, vol.19, issue.24, pp.6696-702, 2013. ,
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion, Pigment Cell Melanoma Res, vol.28, issue.5, pp.607-617, 2015. ,
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.14, p.13, 2014. ,
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, vol.31, pp.1023-1054, 2013. ,
Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in "driver-negative" lung adenocarcinomas, Clin Cancer Res, vol.21, pp.3631-3640, 2015. ,
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing, Clin Cancer Res, vol.22, issue.13, pp.3281-3286, 2016. ,
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases, Acta Neuropathol, vol.123, issue.2, pp.223-256, 2012. ,
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma, Am J Surg Pathol, vol.37, issue.1, pp.61-66, 2013. ,
Minimal functional driver gene heterogeneity among untreated metastases, Science, vol.361, issue.6406, pp.1033-1040, 2018. ,
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma, Melanoma Res, vol.24, issue.5, pp.504-512, 2014. ,
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors, Cancer Discov, vol.2, issue.9, pp.791-798, 2012. ,
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion, Pigment Cell Melanoma Res, vol.28, issue.5, pp.607-617, 2015. ,
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, vol.9, issue.1, p.34, 2017. ,
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade, Cancer Immunol Res, vol.4, issue.11, pp.959-967, 2016. ,
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, Mol Cancer Ther, vol.16, issue.11, pp.2598-2608, 2017. ,